E. Simpson, “Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2)”, J of Skin, vol. 4, no. 6, p. s96, Oct. 2020.